EP1511508A4 - Verfahren zur behandlung dyslipidämischer störungen - Google Patents

Verfahren zur behandlung dyslipidämischer störungen

Info

Publication number
EP1511508A4
EP1511508A4 EP03734054A EP03734054A EP1511508A4 EP 1511508 A4 EP1511508 A4 EP 1511508A4 EP 03734054 A EP03734054 A EP 03734054A EP 03734054 A EP03734054 A EP 03734054A EP 1511508 A4 EP1511508 A4 EP 1511508A4
Authority
EP
European Patent Office
Prior art keywords
apolipoprotein
apoa
complex
administration
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03734054A
Other languages
English (en)
French (fr)
Other versions
EP1511508A2 (de
Inventor
Jean-Louis H Dasseux
Anna A Schwendeman
Thomas J Rea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of EP1511508A2 publication Critical patent/EP1511508A2/de
Publication of EP1511508A4 publication Critical patent/EP1511508A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention provides methods of treating or preventing a disease, condition or disorder associated with dyslipidemia with apolipoprotein-sphingomyelin complexes or pharmaceutical compositions thereof.
  • the invention further provides compositions for treating or preventing a disease, condition or disorder associated with dyslipidemia and methods for the production of the compositions.
  • Circulating cholesterol is carried by plasma lipoproteins — complex particles of lipid and protein composition that transport lipids in the blood.
  • lipoproteins complex particles of lipid and protein composition that transport lipids in the blood.
  • chylomicrons very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL).
  • VLDL very low density lipoprotein
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • Chylomicrons constitute a short-lived product of intestinal fat absorption.
  • VLDL and particularly, LDL are responsible for the delivery of cholesterol from the liver (where it is synthesized or obtained from dietary sources) to extrahepatic tissues, including the arterial walls.
  • HDL by contrast, mediates reverse cholesterol transport (RCT), the removal of cholesterol from extrahepatic tissues to the liver, where it is catabolized, eliminated or recycled. HDL also plays a role in inflammation, transporting oxidized lipids and interleukin.
  • Lipoprotein particles have a hydrophobic core comprised of cholesterol (normally in the form of a cholesteryl ester) and triglycerides. The core is surrounded by a surface coat comprising phospholipids, unesterified cholesterol and apolipoproteins. Apolipoproteins mediate lipid transport, and some may interact with enzymes involved in lipid metabolism.
  • At least ten apolipoproteins have been identified, including: ApoA-I, ApoA-II, ApoA-IN, ApoA-V, ApoB, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, ApoJ and ApoH.
  • Other proteins such as LCAT (lecithinxholesterol acyltransferase), CETP
  • Cardiovascular diseases such as coronary heart disease, coronary artery disease and atherosclerosis are linked overwhelmingly to elevated serum cholesterol levels.
  • atherosclerosis is a slowly progressive disease characterized by the accumulation of cholesterol within the arterial wall.
  • Compelling evidence supports the theory that lipids deposited in atherosclerotic lesions are derived primarily from plasma LDLs; thus, LDLs have popularly become known as "bad" cholesterol.
  • HDL serum levels correlate inversely with coronary heart disease. Indeed, high serum levels of HDLs are regarded as a negative risk factor.
  • RCT reverse cholesterol transport pathway functions to eliminate cholesterol from most extrahepatic tissues and is crucial to maintaining the structure and function of most cells in the body.
  • RCT consists mainly of three steps: (a) cholesterol efflux, i.e., the initial removal of cholesterol from various pools of peripheral cells; (b) cholesterol esterif ⁇ cation by the action of lecithinxholesterol acyltransferase (LCAT), preventing a re-entry of effluxed cholesterol into cells; and (c) uptake of HDL cholesterol and cholesteryl esters to liver cells for hydrolysis, then recycling, storage, excretion in bile or catabolism to bile acids.
  • LCAT lecithinxholesterol acyltransferase
  • LCAT the key enzyme in RCT, is produced by the liver and circulates in plasma associated with the HDL fraction. LCAT converts cell-derived cholesterol to cholesteryl esters, which are sequestered in HDL destined for removal (see Jonas 2000, Biochim. Biophys. Acta 1529(1 -3):245-56). Cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP) contribute to further remodeling of the circulating HDL population. CETP moves cholesteryl esters made by LCAT to other lipoproteins, particularly ApoB-comprising lipoproteins, such as VLDL and LDL. PLTP supplies lecithin to HDL. HDL triglycerides are catabolized by the extracellular hepatic triglyceride lipase, and lipoprotein cholesterol is removed by the liver via several mechanisms.
  • HDL particles are mainly determined by their major apolipoprotein components such as ApoA-I and ApoA-II. Minor amounts of ApoC-I, ApoC-II, ApoC-III, ApoD, ApoA-IV, ApoE, ApoJ have also been observed associated with HDL.
  • HDL exists in a wide variety of different sizes and different mixtures of the above-mentioned constituents, depending on the status of remodeling during the metabolic RCT cascade or pathway.
  • Each HDL particle usually comprises at least one molecule, and usually two to four molecules, of ApoA-I.
  • HDL particles may also comprise only ApoE ( ⁇ -LpE particles), which are known to also be responsible for cholesterol efflux, as described by Prof. Gerd Assmann (see, e.g., von Eckardstein et al, 1994, Curr Opin Lipidol 5 (6): 404- 16).
  • ApoA-I is synthesized by the liver and small intestine as preproapolipoprotein A-I, which is secreted as proapolipoprotein A-I (proApoA-I) and rapidly cleaved to generate the plasma form of ApoA-I, a single polypeptide chain of 243 amino acids (Brewer et al, 1978, Biochem. Biophys. Res. Commun. 80:623-30).
  • PreproApoA-I that is injected experimentally directly into the bloodstream is also cleaved into the plasma form of ApoA-I (Klon et al, 2000, Biophys. J. 79(3): 1679-85; Segrest et ⁇ /., 2000, Curr.
  • ApoA-I comprises 6 to 8 different 22-amino acid ⁇ -helices or functional repeats spaced by a linker moiety that is frequently proline.
  • the repeat units exist in amphipathic helical conformation (Segrest et al, 1974, EERS Lett. 38: 247-53) and confer the main biological activities of ApoA-I, i.e., lipid binding and lecithin cholesterol acyl transferase (LCAT) activation.
  • LCAT lecithin cholesterol acyl transferase
  • ApoA-I forms three types of stable complexes with lipids: small, lipid-poor complexes referred to as pre-/3-l HDL; flattened discoidal particles comprising polar lipids (phospholipid and cholesterol) referred to as pre-/3-2 HDL; and spherical particles, comprising both polar and nonpolar lipids, referred to as spherical or mature HDL (HDLu and HDL 2 ).
  • Most HDL in the circulating population comprise both ApoA-I and ApoA-II (the "AI/AII-HDL fraction"). However, the fraction of HDL comprising only ApoA-I (the "AI-HDL fraction”) appears to be more effective in RCT.
  • LCAT reacts preferentially with discoidal, small (pre-/3) and spherical (i.e., mature) HDL, transferring the 2-acyl group of lecithin or other phosphohpids to the free hydroxyl residue of cholesterol to generate cholesteryl esters (retained in the HDL) and lysolecithin.
  • the LCAT reaction requires ApoA-I as an activator; i.e., ApoA-I is the natural cofactor for LCAT.
  • ApoA-I is the natural cofactor for LCAT.
  • Cholesteryl esters in the mature HDL particles in the ApoAI-HDL fraction are removed by the liver and processed into bile more effectively than those derived from HDL comprising both ApoA-I and ApoA-II (the AI/AII-HDL fraction). This may be owing, in part, to the more effective binding of ApoAI-HDL to the hepatocyte membrane.
  • the existence of an HDL receptor has been hypothesized, and a scavenger receptor, class B, type I (SR-BI) has been identified as an HDL receptor (Acton et al, 1996, Science 271:518-20; Xu et al, 1997, Lipid Res.
  • SR-BI is expressed most abundantly in steroidogenic tissues (e.g., the adrenals), and in the liver (Landschulz et al, 1996, J. Clin. Invest. 98:984-95; Rigotti et al, 1996, J. Biol Chem. 271:33545-49).
  • CETP may also play a role in RCT. Changes in CETP activity or its acceptors, VLDL and LDL, play a role in "remodeling" the HDL population. For example, in the absence of CETP, the HDLs become enlarged particles that are not cleared. (For reviews of RCT and HDLs, see Fielding and Fielding, 1995, J. Lipid Res. 36:211-28; Barrans et al, 1996, Biochem. Biophys. Ada 1300:73-85; Hirano et al, 1997, Arterioscler. Thromb. Vase. Biol. 17(6): 1053-59).
  • HDL also plays a role in the reverse transport of other lipids and in detoxification, i.e., the transport of lipids from cells, organs, and tissues to the liver for catabolism and excretion.
  • lipids include sphingomyelin (SM), oxidized lipids, and lysophophatidylcholine.
  • SM sphingomyelin
  • oxidized lipids oxidized lipids
  • lysophophatidylcholine lysophophatidylcholine
  • the major component of HDL, ApoA-I can associate with SM in vitro.
  • BBSM bovine brain SM
  • a maximum rate of reconstitution occurs at 28°C, the temperature approximating the phase transition temperature for BBSM (Swaney, 1983, J. Biol. Chem. 258(2), 1254-59).
  • BBSM:ApoA-I ratios of 7.5:1 or less (wt wt)
  • a single reconstituted homogeneous HDL particle is formed that comprises three ApoA-I molecules per particle and that has a BBSM:ApoA-I molar ratio of 360: 1.
  • Sphingomyelin is elevated in early cholesterol acceptors (pre-/3-HDL and ⁇ - migrating ApoE-comprising lipoprotein), suggesting that SM might enhance the ability of these particles to promote cholesterol efflux (Dass and Jessup 2000, J. Pharm. Pharmacol 52:731-61; Huang et al, 1994, Proc. Natl Acad. Sci. USA 91:1834-38; Fielding and Fielding 1995, J. Lipid Res. 36:211-28).
  • ApoA-I M or ApoA-Ip are similar to reconstituted HDL particles comprising wild-type ApoA-I in their ability to clear dimyristoylphosphatidylcholine (DMPC) emulsions and their ability to promote cholesterol efflux (Calabresi et al, 1997b, Biochemistry 36:12428-33; Franceschini et al, 1999, Arterioscler. Thromb. Vase. Biol. 19:1257-62; Daum et al, 1999, J. Mol. Med. 77:614-22). In both mutations, heterozygous individuals have decreased levels of HDL but paradoxically, are at a reduced risk for atherosclerosis (Franceschini et al, 1980, J Clin.
  • DMPC dimyristoylphosphatidylcholine
  • HDL particles comprising either variant are capable of LCAT activation, although with decreased efficiency when compared with reconstituted HDL particles comprising wild- type ApoA-I (Calabresi et al, 1997a, Biochem. Biophys. Res. Commun. 232:345-49; Daum et al, 1999, J. Mol Med. 77:614-22).
  • the ApoA-l M mutation is transmitted as an autosomal dominant trait; 8 generations of carriers within a family have been identified (Gualandri et al, 1984, Am. J. Hum. Genet. 37:1083-97).
  • the status of an ApoA-l M carrier individual is characterized by a remarkable reduction in HDL-cholesterol level.
  • carrier individuals do not apparently show any increased risk of arterial disease. Indeed, by examination of genealogical records, it appears that these subjects may be "protected” from atherosclerosis (Sirtori et al, 2001, Circulation, 103: 1949-1954; Roma et al, 1993, J. Clin. Invest. 91(4):1445-520).
  • ApoA-I M has a limited capacity to recruit membrane cholesterol compared with wild-type ApoA-I.
  • nascent HDL formed by the association of ApoA-l M with membrane lipids was predominantly 7.4-nm particles rather than larger 9- and 11-nm complexes formed by wild-type ApoA-I.
  • Dyslipidemic disorders are diseases associated with elevated serum cholesterol and triglyceride levels and lowered serum HDL:LDL ratios, and include hyperlipidemia, especially hypercholesterolemia, coronary heart disease, coronary artery disease, vascular and perivascular diseases, and cardiovascular diseases such as atherosclerosis. Syndromes associated with atherosclerosis such as intermittent claudication, caused by arterial insufficiency, are also included.
  • a number of treatments are currently available for lowering the elevated serum cholesterol and triglycerides associated with dyslipidemic disorders. However, each has its own drawbacks and limitations in terms of efficacy, side-effects and qualifying patient population.
  • Bile-acid-binding resins are a class of drugs that interrupt the recycling of bile acids from the intestine to the liver; e.g., cholestyramine (Questran Light®, Bristol- Myers Squibb), and colestipol hydrochloride (Colestid®, The Upjohn Company). When taken orally, these positively-charged resins bind to the negatively charged bile acids in the intestine. Because the resins cannot be absorbed from the intestine, they are excreted carrying the bile acids with them. The use of such resins at best, however, only lowers serum cholesterol levels by about 20%, and is associated with gastrointestinal side- effects, including constipation and certain vitamin deficiencies. Moreover, since the resins bind other drugs, other oral medications must be taken at least one hour before or four to six hours subsequent to ingestion of the resin; thus, complicating heart patient's drug regimens.
  • Statins are cholesterol lowering agents that block cholesterol synthesis by inhibiting HMGCo A reductase — the key enzyme involved in the cholesterol biosynthetic pathway.
  • Statins e.g., lovastatin (Mevacor®), simvastatin (Zocor®), pravastatin (Pravachol®), fluvastatin (Lescol®) and atorvastatin (Lipitor®), are sometimes used in combination with bile-acid-binding resins.
  • Statins significantly reduce serum cholesterol and LDL-serum levels, and slow progression of coronary atherosclerosis. However, serum HDL cholesterol levels are only moderately increased.
  • the mechanism of the LDL lowering effect may involve both reduction of VLDL concentration and induction of cellular expression of LDL-receptor, leading to reduced production and/or increased catabolism of LDLs.
  • Side effects, including liver and kidney dysfunction are associated with the use of these drugs (The Physicians Desk Reference (56 th ed., 2002) Medical Economics).
  • Niacin (nicotinic acid) is a water soluble vitamin B-complex used as a dietary supplement and antihyperlipidemic agent. Niacin diminishes production of VLDL and is effective at lowering LDL. In some cases, it is used in combination with bile-acid binding resins. Niacin can increase HDL when used at adequate doses, however, its usefulness is limited by serious side effects when used at such high doses. Niaspan® is a form of extended-release niacin that produces fewer side effects than pure niacin. Niacin/Lovastatin (Nicostatin®) is a formulation containing both niacin and lovastatin and combines the benefits of each drug.
  • Fibrates are a class of lipid-lowering drugs used to treat various forms of hyperlipidemia (i.e., elevated serum triglycerides) that may also be associated with hypercholesterolemia. Fibrates appear to reduce the VLDL fraction and modestly increase HDL — however the effects of these drugs on serum cholesterol is variable. In the United States, fibrates such as clofibrate (Atromid-S®), fenofibrate (Tricor®) and bezafibrate (Bezalip®) have been approved for use as antilipidemic drugs, but have not received approval as hypercholesterolemia agents.
  • fibrates such as clofibrate (Atromid-S®), fenofibrate (Tricor®) and bezafibrate (Bezalip®) have been approved for use as antilipidemic drugs, but have not received approval as hypercholesterolemia agents.
  • clofibrate is an antilipidemic agent that acts (via an unknown mechanism) to lower serum triglycerides by reducing the VLDL fraction.
  • serum cholesterol may be reduced in certain patient subpopulations, the biochemical response to the drug is variable, and is not always possible to predict which patients will obtain favorable results.
  • Atromid-S® has not been shown to be effective for prevention of coronary heart disease.
  • the chemically and pharmacologically related drug, gemfibrozil (Lopid®) is a lipid regulating agent that moderately decreases serum triglycerides and VLDL cholesterol, and moderately increases HDL cholesterol — the HDL and HDL 3 subfractions as well as both ApoA-I and A-II (i.e., the AI/AII-HDL fraction).
  • the lipid response is heterogeneous, especially among different patient populations.
  • prevention of coronary heart disease was observed in male patients between 40-55 without history or symptoms of existing coronary heart disease, it is not clear to what extent these findings can be extrapolated to other patient populations (e.g., women, older and younger males).
  • Estrogen treatment is, of course, limited to a specific patient population (postmenopausal women) and is associated with serious side effects including induction of malignant neoplasms, gall bladder disease, thromboembolic disease, hepatic adenoma, elevated blood pressure, glucose intolerance, and hypercalcemia.
  • the need therefore exists for safer drugs that are more efficacious in lowering serum cholesterol, increasing HDL serum levels, preventing and/or treating diseases, conditions or disorders associated with dyslipidemia.
  • HDL as well as recombinant forms of ApoA-I complexed with phosphohpids can serve as sinks / scavengers for apolar or amphipathic molecules, e.g., cholesterol and derivatives (oxysterols, oxidized sterols, plant sterols, etc.), cholesterol esters, phosphohpids and derivatives (oxidized phosphohpids), triglycerides, oxidation products, and lipopolysaccharides (LPS) (see, e.g., Casas et al, 1995, J. Surg. Res. Nov;59(5):544-52).
  • HDL can also serve as also a scavenger for TNF- ⁇ . and other lymphokines.
  • HDL can also serve as a carrier for human serum paraoxonases, e.g.,
  • Paraoxonase an esterase associated with HDL, is important for protecting cell components against oxidation. Oxidation of LDL, which occurs during oxidative stress, appears directly linked to development of atherosclerosis (Aviram, 2000, Free Radic. Res. 33 Suppl:S85-97). Paraoxonase appears to play a role in susceptibility to atherosclerosis and cardiovascular disease (Aviram, 1999, Mol Med. Today
  • PON-1 Human serum paraoxonase
  • HDLs high-density lipoproteins
  • LDL low-density lipoprotein
  • Interventions that preserve or enhance PON-1 activity may help to delay the onset of atherosclerosis and coronary heart disease.
  • HDL further has a role as an antithrombotic agent and fibrinogen reducer, and as an agent in hemorrhagic shock (Cockerill et al, WO 01/13939, published March 1, 2001).
  • HDL, and ApoA-I in particular has been show to facilitate an exchange of lipopolysaccharide produced by sepsis into lipid particles comprising ApoA-I, resulting in the functional neutralization of the lipopolysaccharide (Wright et al, WO9534289, published December 21, 1995; Wright et al, U.S. Patent No. 5,928,624 issued July 27, 1999; Wright et al, U.S. Patent No. 5,932,536, issued August 3, 1999).
  • the invention provides methods of treating or preventing a disease, condition or disorder associated with dyslipidemia, which methods utilize apolipoprotein- sphingomyelin complexes or compositions comprising apolipoprotein-sphingomyelin complexes, e.g., apolipoproteinA-I-SM (ApoA-I-SM).
  • apolipoproteinA-I-SM apolipoproteinA-I-SM
  • apolipoproteins such as ApoA-I are administered in the form of apolipoprotein-sphingomyelin ("Apo-SM”) complexes, far less apolipoprotein is required to achieve the same or better cholesterol mobilization and, hence, therapeutic benefit, than that provided by other apolipoprotein-lipid complexes.
  • Apo-SM apolipoprotein-sphingomyelin
  • soybean phosphatidylcholine (soybeanPC) treatment regimens require administration of from 20-50 mg/kg (or 1-4 g/person) apolipoprotein every 2-5 days (i.v.)
  • treatment regimens according to the invention require the administration of only 0.05 to 25 mg/kg (40 mg to 2 g per person) of apolipoprotein every 2-10 days (i.v.).
  • the methods of the invention reduce by 2- to 25-fold the amount of apolipoprotein required for therapeutic benefit, thereby reducing substantially the cost of treatment, making the treatment regimen more convenient for the patient and perhaps reducing possible adverse effects associated with administration of the drug.
  • the mobilization of cholesterol is significantly sustained for a longer period of time for proApoA-I-SM complexes, i.e., longer than that of conventional apolipoprotein-phospholipid complexes.
  • treatments according to the invention may be less frequent than current treatment protocols, typically about every 2 to 10 days, as compared with about every 2 to 5 days, without loss of therapeutic benefit.
  • a decreased dose may be administered with the same frequency.
  • administration is about every 5 to 10 days, significantly reducing the number of clinic or hospital visits required by the patient.
  • the invention encompasses, in one embodiment, a pharmaceutically acceptable and injectable unit dosage which comprises less than 3500 mg of an apolipoprotein- sphingomyelin complex.
  • the composition comprises less than 1750 mg, less than 1400 mg, less than 700 mg and less than 350 mg per unit dosage form.
  • Use of the ApoA-I-SM complexes according to the invention is also advantageous because lower anticipated doses of the volume of ApoA-I-SM complexes infused or injected leads to faster and easier administration and improved patient comfort.
  • SM is a much more chemically stable lipid than soybean phosphatidylcholine (soybean PC), hence there is greater stability of ApoA-I complexes and longer product shelf-life compared to convention complexes.
  • the methods of the invention provide benefit in virtually any context in which apolipoprotein therapy is advantageous.
  • the methods of the invention may be advantageously used to treat or prevent virtually any disease, condition or disorder associated with dyslipidemia that is treatable with apolipoproteins.
  • a dosage of apolipoprotein from 2- to 25-fold less than the effective dosage of apolipoprotein alone, or apolipoprotein and soybean PC may be administered.
  • Apo-SM complexes are administered systemically, they can be used to treat or prevent atherosclerosis and stenosis, mobilizing cholesterol from a patient's entire vasculature including small vessels.
  • FIG. 1 shows absolute changes in levels of HDL fraction of unesterified cholesterol following administration of 15mg/kg doses of r-proApoA-I-SM and r-proApoA-I-POPC complexes.
  • X-axis time (hours).
  • Y-axis Change in free HDL cholesterol (mg/dL).
  • the invention provides methods of treating or preventing a disease, condition or disorder associated with dyslipidemia utilizing apolipoprotein-sphingomyelin complexes or pharmaceutical compositions comprising apolipoprotein-sphingomyelin ("Apo-SM”) complexes, e.g., apolipoproteinA-I-SM (ApoA-I-SM).
  • Apo-SM apolipoprotein-sphingomyelin
  • dislipidemia refers to an abnormally elevated or decreased level of lipid in the blood plasma, including, but not limited to, the altered level of lipid associated with the following conditions: coronary heart disease; coronary artery disease; cardiovascular disease, hypertension, restenosis, vascular or perivascular diseases; dyslipidemic disorders; dyslipoproteinemia; high levels of low density lipoprotein cholesterol; high levels of very low density lipoprotein cholesterol; low levels of high density lipoproteins; high levels of lipoprotein Lp(a) cholesterol; high levels of apolipoprotein B; atherosclerosis (including treatment and prevention of atherosclerosis); hyperhpidemia; hypercholesterolemia; familial hypercholesterolemia (FH); familial combined hyperhpidemia (FCH); lipoprotein lipase deficiencies, such as hypertriglyceridemia, hypoalphalipoproteinemia, and hypercholesterolemialipoprotein.
  • coronary heart disease coronary artery disease
  • cardiovascular disease hypertension, restenosis, vascular or perivascular diseases
  • apolipoproteins such as Apo-AI are administered in the form of apolipoprotein- sphingomyelin (Apo-SM) complexes
  • Apo-SM apolipoprotein- sphingomyelin
  • the invention encompasses the treatment of diseases or disorders associated with dyslipidemia in a human in need thereof which comprises administering a therapeutically effective amount of an apolipoprotein-sphingomyelin complex to said human.
  • the complex is a solid, including a lyophilized solid, suitable for reconstitution into a solution of apolipoprotein-sphingomyelin discoidal particles.
  • the administration is preferably parenteral, especially intravenous, bolus injection , intramuscular, subcutaneous and the like.
  • the methods of the invention use 2- to 25-fold less apolipoprotein than is required when a complex of apolipoprotein and soybean PC is administered.
  • treatments according to the invention may be applied less frequently, typically about every 2 to 10 days, without loss of therapeutic benefit.
  • a decreased dose may be administered with the same frequency.
  • treatment may be applied every 5 to 10 days, significantly reducing the number of clinic or hospital visits required by the patient.
  • Use of the Apo A-I-SM complexes according to the invention is also advantageous because lower anticipated doses of the volume of Apo A-I-SM complexes infused or injected leads to faster and easier administration and improved patient comfort.
  • Use of the ApoA-I-SM complexes according to the invention is further advantageous because SM is a much more chemically stable lipid than soybean phosphatidylcholine (soybean PC), hence there is greater stability of Apo A-I complexes and longer product shelf-life compared to convention complexes.
  • the administration methods of the invention provide benefit in virtually any context in which apolipoprotein therapy is advantageous.
  • the methods of the invention may be advantageously used to treat or prevent virtually any disease, condition or disorder associated with dyslipidemia, or symptom thereof, responsive to apolipoproteins.
  • a dosage of apolipoprotein from 2- to 25-fold less than the effective dosage currently known in the art would be expected to be efficacious in treating or preventing the disease or in bringing about an ameliorative effect.
  • Apo-SM complexes are administered systemically, they can be used to treat or prevent atherosclerosis and stenosis, mobilizing cholesterol from a patient's entire vasculature including small vessels.
  • the invention is illustrated by working examples that demonstrate that the ApoA-I-SM complexes of the invention can increase the concentration of HDL and increase cellular cholesterol efflux.
  • Use of the ApoA-I-SM complexes disclosed herein in vivo in animal models results in an increase of HDL cholesterol levels in plasma, which is an indicative of cholesterol mobilization efflux by recombinant HDL particles (i.e., ApoAI-SM-complexes).
  • the increase of HDL cholesterol concentration induced by injection of ApoAI-SM particles is significantly greater than that induced by ApoAI-phosphatidylcholine particles (such as ApoAI-SoybeanPC and ApoAI-POPC).
  • the invention utilizes apolipoprotein compositions in which an apolipoprotein is complexed with sphingomyelin ("Apo-SM complexes").
  • any apolipoprotein or apolipoprotein derivative or analogue that provides therapeutic benefit when used to treat or prevent the above-listed disorders may be complexed with SM and advantageously administered at lower than conventional doses according to the invention.
  • any protein or peptide of an ⁇ -helical nature that also activates LCAT may be used.
  • Suitable apolipoproteins include, but are not limited to, preproapolipoprotein forms of ApoA-I, ApoA-II, ApoA-IV, ApoA-V and ApoE; pro- and mature forms of human ApoA-I, ApoA-II, ApoA-IV, and ApoE; and active polymorphic forms, isoforms, variants and mutants as well as truncated forms, the most common of which are ApoA-lMiiano (ApoA-Ijv and ApoA-Ip ar is (ApoA-Ip).
  • Apolipoproteins utilized by the invention also include recombinant or purified apolipoproteins.
  • Apolipoprotein-SM complexes that may be used according to the methods of the invention include those disclosed in U.S. Patent No. 6,287,590, issued September 11, 2001, which is incorporated herein by reference in its entirety.
  • Apolipoproteins utilized by the invention further include peptides that correspond to apolipoproteins as well as agonists that mimic the activity of ApoA-I, ApoA-I M , ApoA-II, ApoA-IV, and ApoE, such as those disclosed in U.S. Patent Nos. 6,004,925, 6,037,323 and 6,046,166 (issued to Dasseux et al), and in U.S. Patent No. 5,840,688 (issued November 24, 1998 to Tso); and which are incorporated herein by reference in their entireties.
  • Such peptides can be synthesized or manufactured using any technique for peptide synthesis known in the art, see, e.g., the techniques described in U.S. Patent Nos. 6,004,925, 6,037,323 and 6,046,166.
  • Stable preparations that have a long shelf life may be made by lyophilizing the peptides — either to prepare bulk for reformulation, or to prepare individual aliquots or dosage units that can be reconstituted by rehydration with sterile water or an appropriate sterile buffered solution prior to administration to a subject.
  • the Apo-SM complexes may include a single type of apolipoprotein, or mixtures of two or more different apolipoproteins, which may be derived from the same or different species.
  • the Apo-SM complexes will preferably comprise apolipoproteins derived from the animal species being treated, in order to avoid inducing an immune response to the therapy.
  • the apolipoprotein(s) may be complexed with many types of SM analogues or derivatives.
  • SM is a phospholipid very similar in structure to phosphatidylcholine, but with an amide bond instead of an ester bond.
  • SM is not a substrate for LCAT and generally cannot be hydro lyzed by it. It can act, however, as an inhibitor of LCAT or can decrease LCAT activity by diluting the concentration of the substrate phospholipid. Because SM is not hydrolyzed, it remains longer in the circulation. This feature permits complexes comprising Apo-SM to have longer duration of pharmacological effect (mobilization of cholesterol) and to pick up more lipids, in particular cholesterol. This will results in less frequent or smaller doses necessary for treatment with Apo-SM particles.
  • the apolipoprotein(s) may be complexed with SM derived from virtually any source.
  • the SM may be obtained from milk, egg or brain.
  • SM analogues or derivatives may also be used.
  • Non-limiting examples of useful SM analogues and derivatives include, but are not limited to, palmitoylsphingomyelin and stearoylsphingomyelin.
  • the sphingomyelin may be artificially enriched in one particular saturated or unsaturated acyl chain.
  • milk sphingomyelin (Avanti Phospholipid, Alabaster, AL) is characterized by long saturated acyl chains. Milk sphingomyelin comprises about 20% of C16:0 (16 carbon, saturated) acyl chain compared to the 80% comprised in egg sphingomyelin.
  • milk sphingomyelin can be enriched in one particular acyl chain to have a composition in acyl chain comparable to, e.g., egg sphingomyelin.
  • Acyl chains that may be utilized by the invention include, but are not limited to saturated acyl chains (such as dipalmitoyl, distearoyl, diarachidonyl, and dibenzoyl acyl chains), unsaturated chains (such as dioleoyl chains), mixed chains of saturated and unsaturated acyl chains (such as palmitoyl or oleoyl chains), saturated and/or unsaturated chains of mixed lengths, and ether analogueues of saturated and unsaturated acyl chains.
  • saturated acyl chains such as dipalmitoyl, distearoyl, diarachidonyl, and dibenzoyl acyl chains
  • unsaturated chains such as dioleoyl chains
  • mixed chains of saturated and unsaturated acyl chains such as palmitoyl or oleoyl chains
  • saturated and/or unsaturated chains of mixed lengths such as palmitoyl or oleoyl chains
  • the SM may be semi-synthetic such that it has a particular acyl chain.
  • milk sphingomyelin can be first purified from milk, then one particular acyl chain, e.g., the C16:0 acyl chain, can be cleaved and replaced by another acyl chain (preferably palmitic acid or oleic acid).
  • SM can also be entirely synthesized, by e.g., large-scale synthesis. See, e.g.,
  • a predefined saturation level and fatty acid composition is selected for the synthetic SM.
  • the complexes may optionally also include one or more other phosphohpids in addition to the SM.
  • phospholipid may be used, including, but not limited to, small alkyl chain phosphohpids, phosphatidylcholine (PC), egg phosphatidylcholine, soybean phosphatidylcholine, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine l-myristoyl-2-palmitoylphosphatidylcholine, 1 -palmitoyl-2-myristoylphosphatidylcholine, 1 -palmitoyl-2-stearoylphosphatidylcholine, 1 -stearoyl-2-palmitoylphosphatidylcholine, 1 -palmitoyl-2-oleoylphosphatidylcholine, 1 - oleoyl-2-palmitylphosphatidylcholine, dioleoylphosphatidylcholine dioleoylphosphatidylcho
  • compositions will typically comprise about 40-85 wt% total phospholipid and about 60-15 wt% total apolipoprotein. (This range corresponds to roughly 1 :25 to 1 :200 molar ratio of apolipoprotein to phospholipid). If an optional second phospholipid is included, the sphingomyelin should typically comprise from about 25 to 75 wt% of the total phospholipid component, with the balance being the second type of phospholipid.
  • the apolipoprotein-phospholipid complexes can be complexed in phospholipid:apolipoprotein ratios (Ri) that vary depending on the apolipoprotein and the nature of the SM and other phospholipid(s) comprised in the complex, as well as the expected size of the complex ranging in size from 2-12 nm.
  • the phospholipid: ApoA-I molar ratio may vary from 25 to 200.
  • the percentage of SM in the complex may vary from 25% to 100% of the total phospholipid composition.
  • the complexes may optionally also include paraoxonase (PON), antioxidants, cyclodextrins or other materials that help trap cholesterol in the core or the surface of the HDL- like particle.
  • HDL particle may optionally be pegylated (e.g., covered with polyethylene glycol or other polymer) to increase circulation half-life.
  • Apolipoprotein, phospholipid, and Apo-phospholipid complexes utilized by the invention also include molecules that are labeled with any art-known detectable marker, including stable isotopes (e.g., 13 C, 15 N, 2 H, etc.); radioactive isotopes (e.g., u C, 3 H, 125 I, etc.); fluorophores; chemiluminescers; or enzymatic markers.
  • stable isotopes e.g., 13 C, 15 N, 2 H, etc.
  • radioactive isotopes e.g., u C, 3 H, 125 I, etc.
  • fluorophores chemiluminescers
  • chemiluminescers chemiluminescers
  • enzymatic markers e.g., enzymatic markers.
  • Apo-SM complexes can be prepared in a variety of forms, including, but not limited to vesicles, liposomes, proteoliposomes, micelles, and discoidal particles.
  • a variety of methods well known to those skilled in the art can be used to prepare the Apo- SM complexes.
  • a number of available techniques for preparing liposomes or proteoliposomes may be used.
  • apolipoprotein can be co-sonicated (using a bath or probe sonicator) with the appropriate lipid (i.e., sphingomyelin) to form complexes.
  • apolipoprotein can be combined with preformed lipid vesicles resulting in the spontaneous formation of Apo-SM complexes.
  • the Apo-SM complexes can also be formed by a detergent dialysis method; e.g., a mixture of Apo, SM and a detergent such as cholate is dialyzed to remove the detergent and reconstituted to form Apo-SM complexes (see, e.g., Jonas et ⁇ l, 1986, Methods Enzymol. 128:553-82), or by using an extruder device or by homogenization.
  • a detergent dialysis method e.g., a mixture of Apo, SM and a detergent such as cholate is dialyzed to remove the detergent and reconstituted to form Apo-SM complexes (see, e.g., Jonas et ⁇ l, 1986, Methods Enzymol. 128:553-82), or by using an extruder device or by homogenization.
  • Apo-SM complexes can be prepared by the cholate dispersion method as described in Section 6.1 (Example 1). Briefly, dry lipid is hydrated in NaHCO 3 buffer, then vortexed and sonicated until all lipid is dispersed. Cholate solution is added, the mixture is incubated for 30 minutes, with periodic vortexing and sonicating, until it turns clear, indicating that the lipid cholate micelles are formed. ProApoA-I in NaHCO 3 buffer is added, and the solution incubated for 1 hour at approximately 37°C -50°C. The ratio of lipid:proApoA-I in the solution can be from 1:1 to 200:1 (mole/mole), but in a preferred embodiment, the ratio is 2:1 weight of lipid to weight of protein (wt/wt) .
  • Cholate can be removed by methods well known in the art.
  • cholate can be removed by dialysis, ultrafiltration or by removal of cholate molecules by adsorption absorption onto an affinity bead or resin.
  • the affinity beads e.g., BIO-BEADS® (Bio-Rad Laboratories) are added to the preparation of Apo- lipid complexes and cholate to adsorb the cholate.
  • the preparation e.g., a micellar preparation of the Apo-SM complexes and cholate, is passed over a column packed with affinity beads.
  • cholate is removed from a preparation of proApoA-I- lipid complexes by loading the preparation onto BIO-BEADS® within a syringe. The syringe is then sealed with barrier film and incubated with rocking at 4°C overnight.
  • the cholate is remove by injecting the solution through BIO-BEADS®, where it is adsorbed by the beads.
  • the Apo-SM complexes have an increased half-life in the circulation when the complexes have a similar size and density to HDL, especially to the HDLs in the pre-jS-1 or pre-j3-2 HDL populations.
  • Stable preparations having a long shelf life may be made by lyophilization—the co-lyophilization procedure described below being a preferred approach due to the stability of the resulting formulation and the ease of formulation/particle preparation process.
  • Co-lyophilization methods are also described in U.S. Patent No. 6,287,590 (entitled Peptide/lipid complex formation by co-lyophilization, by Dasseux, issued September 11, 2001), which is incorporated herein by reference in its entirety.
  • the lyophilized Apo-SM complexes can be used to prepare bulk for pharmaceutical reformulation, or to prepare individual aliquots or dosage units that can be reconstituted by rehydration with sterile water or an appropriate buffered solution prior to administration to a subject.
  • apolipoprotein may be complexed with a variety of sphingomyelins.
  • the sphingomyelin may be artificially enriched in one particular saturated or unsaturated acyl chain.
  • milk sphingomyelin (Avanti Phospholipid, Alabaster, AL) is characterized by long saturated acyl chains. Milk sphingomyelin comprises about 20% ofC16:0 (16 carbon, saturated) acyl chain compared to the 80% comprised in egg sphingomyelin.
  • milk sphingomyelin can be enriched in one particular acyl chain to have a composition in acyl chain comparable to, e.g., egg sphingomyelin.
  • Acyl chains that may be utilized by the invention include, but are not limited to, saturated acyl chains (such as dipalmitoyl, distearoyl, diarachidonyl, and dibehenoyl acyl chains), unsaturated chains (such as dioleoyl chains), mixed chains of saturated and unsaturated acyl chains (such as palmitoyl or oleyl chains), saturated and/or unsaturated chains of mixed lengths, and ether analogueues of saturated and unsaturated acyl chains.
  • saturated acyl chains such as dipalmitoyl, distearoyl, diarachidonyl, and dibehenoyl acyl chains
  • unsaturated chains such as dioleoyl chains
  • mixed chains of saturated and unsaturated acyl chains
  • a source of natural sphingomyelin is selected to avoid contamination by prions (e.g., in brain sphingomyelin) or viral contamination (e.g., in egg sphingomyelin).
  • fully synthetic SM is selected to avoid contamination.
  • a SM with a high saturation state is used to improve chemical stability of the Apo-AI-SM complex.
  • the SM may be semi-synthetic such that it has a particular acyl chain.
  • milk sphingomyelin can be first purified from milk, then one particular acyl chain, e.g., the C16:0 acyl chain, can be cleaved and replaced by another acyl chain (preferably palmitic acid or oleic acid).
  • SM can also be entirely synthesized, by e.g., large-scale synthesis (see, e.g., Dong et al, U.S. Patent No. 5,220,043, entitled Synthesis of D-erythro-sphingomyelins, issued June 15, 1993 ; Weis, 1999, Chem. Phys. Lipids 102(l-2):3-12).
  • a predefined saturation level and fatty acid composition is selected for the synthetic SM.
  • the resulting complexes may be reconstituted immediately before use.
  • the resulting complexes usually need not be further purified after formation and before use.
  • the production method can be easily scaled up and is suitable for GMP manufacture (i.e., in an endotoxin-free environment).
  • co-lyophilization methods commonly known in the art are used to prepare Apo-SM complexes.
  • the co-lyophilization steps include solubilizing Apo and lipid in organic solvent of solvent mixture, or solubilizing Apo and lipid separately and mixing them together.
  • the desirable characteristics of solvent or solvent mixture are: (i) a medium relative polarity to be able to dissolve hydrophobic lipids and amphipatic protein, (ii) solvents should be class 2 or 3 solvent according to FDA solvent guidelines (Federal Register, volume 62, No.
  • glacial acetic acid is used.
  • Combinations of e.g., methanol, glacial acetic acid, xylene, or cyclohexane may also be used.
  • the Apo/Lipid solution is then lyophilized to obtain homogeneous Apo/lipid powder.
  • the lyophilization conditions can be optimized to obtain fast evaporation of solvent with minimal amount of residual solvent in the lyophilized Apo/lipid powder.
  • the selection of freeze-drying conditions can be determined by the skilled artisan, and depends on the nature or solvent, type and dimensions of the receptacle, e.g., vial, holding solution, fill volume, and characteristics of freeze-dryer used.
  • the concentration of lipid/ Apo solution prior to the lyophilization, for organic solvent removal and successful formation of complexes is preferably 10 to 50 mg/ml concentration of Apo and 20 to 100 mg/ml concentrations of lipid.
  • the Apo-lipid complexes form spontaneously after hydration of Apo-lipid lyophilized powder with an aqueous media of appropriate pH and osmolality.
  • the media may also contain stabilizers such as sucrose, trehalose, glycerin and others.
  • the solution must be heated several times above transition temperature for lipids for complexes to form.
  • the ratio of lipid to protein for successful formation of Apo-SM complexes can be from 1:1 to 200:1 (mole/mole), and is preferably 2:1 weight of lipid to weight of protein (wt/wt). Powder is hydrated to obtain final complex concentration of 5-30 mg/ml expressed in protein equivalents.
  • Apo powder is obtained by freeze-drying Apo solution in NH HCO 3 aqueous solution.
  • a homogeneous solution of Apo and lipid i.e., sphingomyelin
  • the solution is then lyophilized, and HDL-like Apo-lipid complexes are formed by hydration of lyophilized powder with aqueous media.
  • the another preferred method is homogenization.
  • This method may be used to prepare Apo soybean-PC complexes and is routinely used for formulation of AI- M ii ano -POPC complexes. Homogenization can be easily adapted for formation of Apo-SM complexes. Briefly, this method comprises forming a suspension of lipids in aqueous solution of Apo by UltraturexTM, and homogenization of formed lipid-protein suspension using high-pressure homogenizer until suspension becomes clear-opalescent solution and complexes are formed. Elevated temperatures above lipid transition are used during homogenization. Solution is homogenized for extended period of time 1-14 hours and elevated pressure.
  • Apo-SM complexes are formed by co-lyophilization of phospholipid with peptide or protein solutions or suspensions.
  • the homogeneous solution of peptide/protein and SM (plus any other phospholipid of choice) in an organic solvent or organic solvent mixture can be lyophilized, and Apo-SM complexes can be formed spontaneously by hydration of the lyophilized powder with an aqueous buffer.
  • organic solvents or their mixtures are include, but are not limited to, acetic acid, acetic acid and xylene, acetic acid and cyclohexane, and methanol and xylene.
  • a suitable proportion of protein (peptide) to lipid can be determined empirically so that the resulting complexes possess the appropriate physical and chemical properties; i.e., usually (but not necessarily) similar in size to HDL.
  • the resulting mixture of Apo and lipid in solvent is frozen and lyophilized to dryness. Sometimes an additional solvent must be added to the mixture to facilitate lyophilization.
  • This lyophilized product can be stored for long periods and will remain stable.
  • the lyophilized product can be reconstituted in order to obtain a solution or suspension of the Apo-lipid complex.
  • the lyophilized powder is rehydrated with an aqueous solution to a suitable volume (typically 5-20 mg Apo-SM complex/ml) which is convenient for e.g., intravenous injection.
  • a suitable volume typically 5-20 mg Apo-SM complex/ml
  • the lyophilized powder is rehydrated with phosphate buffered saline, saline bicarbonate, or a physiological saline solution.
  • the mixture may be agitated or vortexed to facilitate rehydration.
  • the reconstitution step should be conducted at a temperature equal to or greater than the phase transition temperature of the lipid component of the complexes. Within minutes of reconstitution, a clear preparation of reconstituted Apo- lipid complexes will result.
  • An aliquot of the resulting reconstituted preparation can be characterized to confirm that the complexes in the preparation have the desired size distribution; e.g., the size distribution of HDL.
  • Characterization of the reconstituted preparation can be performed using any method known in the art, including, but not limited to, size exclusion filtration, gel filtration, column filtration, and gel permeation chromatography. For example, after hydration of lyophilized Apo-lipid powder or at the end of homogenization or cholate dialysis formed Apo-lipid HDL-like particles are characterized with respect to their size, concentration, final pH and osmolality of resulting solution, in some instances integrities of lipid and apolipoprotein are characterized. The size of the resulting Apo-lipid particles is determinative of their efficacy, therefore making this measurement is preferred for characterization of the particles.
  • GPC gel permeation chromatography
  • a high pressure liquid chromatography system equipped with a 1x30 cm SuperdexTM column (Pharmacia Biotech) and UV-detector may be used.
  • Complexes are eluted with bicarbonate buffered saline comprised of 140 mM NaCl and 20 mM sodium bicarbonate delivered with 0.5 ml/min flow rate. A typical amount of complex injected is 0.1 to 1 mg based on protein weight. The complexes are monitored by absorbance at 280 nm.
  • Protein and lipid concentration of Apo-lipid particles solution can be measured by any method known in the art, including, but not limited to, protein and phospholipid assays as well as by chromatographic methods such as HPLC, gel filtration chromatography, GC coupled with various detectors including mass spectrometry, UV or diode-array, fluorescent, elastic light scattering and others.
  • chromatographic methods such as HPLC, gel filtration chromatography, GC coupled with various detectors including mass spectrometry, UV or diode-array, fluorescent, elastic light scattering and others.
  • the integrity of lipid and proteins can be also determined by the same chromatographic techniques as well as peptide mapping, SDS-page gel, N- and C-terminal sequencing for proteins and standard assays to determine lipid oxidation for lipids.
  • compositions utilized by the invention comprise Apo-SM complexes as the active ingredient in a pharmaceutically acceptable carrier suitable for administration and delivery in vivo. Since peptides may comprise acidic and/or basic termini and/or side chains, peptides can be included in the compositions in either the form of free acids or bases, or in the form of pharmaceutically acceptable salts.
  • injectable compositions include sterile suspensions, solutions or emulsions of the active ingredient in aqueous or oily vehicles.
  • the compositions can also comprise formulating agents, such as suspending, stabilizing and/or dispersing agent.
  • compositions for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, and can comprise added preservatives.
  • a compositions is preferably supplied in an infusion bag made of material compatible with Apo-lipid complexes, such as ethylene vinyl acetate or any other compatible material known in the art.
  • the injectable compositions can be provided in powder form for reconstitution with a suitable vehicle, including but not limited to, sterile pyrogen free water, buffer, dextrose solution, etc., before use.
  • a suitable vehicle including but not limited to, sterile pyrogen free water, buffer, dextrose solution, etc.
  • Apo can be lyophilized, or co-lyophilized Apo-SM complexes may be prepared.
  • the stored compositions can be supplied in unit dosage forms and reconstituted prior to use in vivo.
  • the active ingredient can be formulated as a depot composition, for administration by implantation; e.g., subcutaneous, intradermal, or intramuscular injection.
  • Apo-lipid complex or Apolipoprotein alone may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or in phospholipid foam or ion exchange resins.
  • transdermal delivery systems manufactured as an adhesive disc or patch that slowly releases the active ingredient for percutaneous absorption can be used.
  • permeation enhancers can be used to facilitate transdermal penetration of the active ingredient.
  • a particular benefit can be achieved by incorporating the Apo-SM complexes utilized by the invention into a nitroglycerin patch for use in patients with ischemic heart disease and hypercholesterolemia.
  • the compositions can, if desired, be presented in a pack or dispenser device that may comprise one or more unit dosage forms comprising the active ingredient.
  • the pack can for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device can be accompanied by instructions for administration.
  • the Apo-SM complexes utilized by the invention can be used to treat or prevent virtually any disease, condition or disorder responsive to apolipoproteins or other apolipoprotein-phospho lipid particles (e.g., ApoAI-SoybeanPC, ApoAI-POPC), including but not limited to, coronary heart disease; coronary artery disease; cardiovascular disease, hypertension, restenosis, vascular or perivascular diseases; dyslipidemic disorders; dyslipoproteinemia; high levels of low density lipoprotein cholesterol; high levels of very low density lipoprotein cholesterol; low levels of high density lipoproteins; high levels of lipoprotein Lp(a) cholesterol; high levels of apolipoprotein B; atherosclerosis (including treatment and prevention of atherosclerosis); hyperhpidemia; hypercholesterolemia; familial hypercholesterolemia (FH); familial combined hyperhpidemia (FCH); lipoprotein lipase deficiencies, such as hypertriglyceridemia, hypoalphalipoproteinemia, and hypercholesterolemia
  • the methods of the invention encompass a method of treating or preventing a disease associated with dyslipidemia, comprising administering to a subject a composition comprising an apolipoprotein and sphingomyelin in an amount effective to achieve a serum level of free or complexed apolipoprotein in the range of 10 mg/dL to 300 mg/dL above a baseline (initial) level before administration between 5 minutes and 1 day after administration.
  • the methods of the invention encompass a method of treating or preventing a disease associated with dyslipidemia, comprising administering to a subject an apolipoprotein-sphingomyelin complex in an amount effective to achieve a circulating plasma concentrations of a HDL-cholesterol fraction between 10% and 1000% of the initial HDL-cholesterol fraction concentration between 5 minutes and lday after administration.
  • the methods of the invention encompass a method of treating or preventing a disease associated with dyslipidemia, comprising administering to a subject an apolipoprotein-sphingomyelin complex in an amount effective to achieve a circulating plasma concentration of a HDL-cholesterol fraction between 30 and 300 mg/dL between 5 minutes and 1 day after administration.
  • the methods of the invention encompass a method of treating or preventing a disease associated with dyslipidemia, comprising administering to a subject an apolipoprotein-sphingomyelin complex in an amount effective to achieve a circulating plasma concentrations of cholesteryl esters between 30 and 300 mg/dL between 5 minutes and 1 day after administration.
  • the Apo-SM complexes can be used alone or in combination therapy with other drugs used to treat or prevent the foregoing conditions.
  • Such therapies include, but are not limited to simultaneous or sequential administration of the drugs involved.
  • the Apo-SM formulations can be administered with any one or more of the cholesterol lowering therapies currently in use; e.g., bile-acid resins, niacin, statins, and/or fibrates.
  • Such a combined regimen may produce particularly beneficial therapeutic effects since each drug acts on a different target in cholesterol synthesis and transport; i.e., bile-acid resins affect cholesterol recycling, the chylomicron and LDL population; niacin primarily affects the VLDL and LDL population; the statins inhibit cholesterol synthesis, decreasing the LDL population (and perhaps increasing LDL receptor expression); whereas the Apo-SM complexes affect RCT, increase HDL, and promote cholesterol efflux.
  • bile-acid resins affect cholesterol recycling, the chylomicron and LDL population
  • niacin primarily affects the VLDL and LDL population
  • statins inhibit cholesterol synthesis, decreasing the LDL population (and perhaps increasing LDL receptor expression)
  • the Apo-SM complexes affect RCT, increase HDL, and promote cholesterol efflux.
  • the Apo-SM complexes may be used in conjunction with fibrates to treat or prevent coronary heart disease; coronary artery disease; cardiovascular disease, hypertension, restenosis, vascular or perivascular diseases; dyslipidemic disorders; dyslipoproteinemia; high levels of low density lipoprotein cholesterol; high levels of very low density lipoprotein cholesterol; low levels of high density lipoproteins; high levels of lipoprotein Lp(a) cholesterol; high levels of apolipoprotein B; atherosclerosis (including treatment and prevention of atherosclerosis); hyperhpidemia; hypercholesterolemia; familial hypercholesterolemia (FH); familial combined hyperhpidemia (FCH); lipoprotein lipase deficiencies, such as hypertriglyceridemia, hypoalphalipoproteinemia, and hypercholesterolemialipoprotein.
  • coronary artery disease cardiovascular disease, hypertension, restenosis, vascular or perivascular diseases
  • dyslipidemic disorders dyslipoproteinemia
  • high levels of low density lipoprotein cholesterol high levels of very low density
  • Apo-SM complexes utilized by the invention may be administered by any suitable route that ensures bioavailability in the circulation.
  • An important feature of the invention is that Apo-SM complexes may be administered in doses less than 1-10% of the effective dose required for apolipoprotein (Apo) or Apo peptide administered alone, and in doses 2-25 fold less than the effective dose required for Apo-soybean PC (or Apo- egg PC or Apo-POPC) administration.
  • the Apo-SM complexes utilized by the invention are administered in dosages that increase the small HDL fraction, and preferably, the pre ⁇ - (and pre- 7), and pre-/3-like HDL fraction.
  • Administration can best be achieved by parenteral routes of administration, including intravenous (IV), intramuscular (IM), intradermal, subcutaneous (SC), and intraperitoneal (P) injections.
  • administration is by a perfuser, an infiltrator or a catheter.
  • the Apo-SM complexes are administered by injection, by a subcutaneously implantable pump or by a depot preparation, in amounts that achieve a circulating serum concentration equal to that obtained through parenteral administration.
  • Administration can be achieved through a variety of different treatment regimens. For example, several intravenous injections can be administered periodically during a single day, with the cumulative total volume of the injections not reaching the daily toxic dose. Alternatively, one intravenous injection can be administered about every 3 to 15 days, preferably about every 5 to 10 days, and most preferably about every 10 days. In yet another alternative, an escalating dose can be administered, starting with about 1 to 5 doses at a dose between (50-200mg) per administration, then followed by repeated doses of between 200 mg and 1 g per administration. Depending on the needs of the patient, administration can be by slow infusion with a duration of more than one hour, by rapid infusion of one hour or less, or by a single bolus injection.
  • apolipoprotein-SM is parenterally administered, e.g., by injection, then it is toxic at a dose of 200 mg/kg.
  • injections are given at a lower dosage for several days, then gradually increased, the recipient will adapt to the administration and a higher final dosage can be achieved.
  • an injection can be administered on two sequential days at a concentration of 10 mg/kg, followed by injection on the next two sequential days at a concentration of 20 mg/kg, followed by injection on the next two sequential days at a concentration of 30 mg/kg followed by injection on subsequent days of 40 mg/kg per day.
  • apolipoprotein-SM complexes can be administered for up to two weeks without problems of toxicity.
  • Other routes of administration may be used.
  • absorption through the gastrointestinal tract can be accomplished by oral routes of administration (including but not limited to ingestion, buccal and sublingual routes) provided appropriate formulations (e.g., enteric coatings) are used to avoid or minimize degradation of the active ingredient, e.g., in the harsh environments of the oral mucosa, stomach and/or small intestine.
  • appropriate formulations e.g., enteric coatings
  • administration via mucosal tissue such as vaginal and rectal modes of administration may be utilized to avoid or minimize degradation in the gastrointestinal tract.
  • the formulations of the invention can be administered transcutaneously (e.g., transdermally), or by inhalation. It will be appreciated that the preferred route may vary with the condition, age and compliance of the recipient. The actual dose of Apo-SM complexes will vary with the route of administration.
  • the dose is adjusted to achieve a serum level of free or complexed apolipoprotein in the range of 10 mg/dl to 300 mg/dl above a baseline (initial) level before administration between 5 minutes and 1 day after administration.
  • the baseline level is the initial apolipoprotein level prior to administration of the Apo-SM complexes.
  • the dose is adjusted to achieve a circulating plasma concentrations of a HDL-cholesterol fraction between 10% and 1000% of the initial HDL-cholesterol fraction concentration between 5 minutes and 1 day after intravenous administration.
  • the dose is adjusted to achieve a temporary or permanent circulating plasma concentrations of a HDL-cholesterol fraction between 30 and 300 mg/dl between 5 minutes and 1 day after intravenous administration.
  • the dose is adjusted to achieve a temporary or permanent circulating plasma concentrations of cholesteryl esters between 30 and 300 mg/dl between 5 minutes and 1 day after intravenous administration.
  • Data obtained in animal model systems described in U.S. Patent Nos. 6,004,925, 6,037,323 and 6,046,166 (issued to Dasseux et al, incorporated herein by reference in their entireties) show that ApoA-I peptides associate with the HDL component, and have a projected half-life in humans of about five days.
  • Apo-SM complexes can be administered by intravenous injection at a dose between about O.lg - lg of Apo-SM per administration every 2 to 10 days per average sized human.
  • Toxicity and therapeutic efficacy of the various Apo-SM complexes can be determined using standard pharmaceutical procedures in cell culture or experimental animals for determining the LD 5 o (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD 50 /ED 50 .
  • Apo-SM complexes that exhibit large therapeutic indices are preferred.
  • Patients can be treated from a few days to several weeks before a medical act (e.g., preventive treatment), or during or after a medical act.
  • Administration can be concomitant to or contemporaneous with another invasive therapy, such as, angioplasty, carotid ablation, rotoblader or organ transplant (e.g., heart, kidney, liver, etc.).
  • Apo-SM complexes are administered to a patient whose cholesterol synthesis is controlled by a statin or a cholesterol synthesis inhibitor.
  • Apo-SM complexes are administered to a patient undergoing treatment with a binding resin, e.g., a semi-synthetic resin such as cholestyramine, or with a fiber, e.g., plant fiber, to trap bile salts and cholesterol, to increase bile acid excretion and lower blood cholesterol concentrations.
  • a binding resin e.g., a semi-synthetic resin such as cholestyramine
  • a fiber e.g., plant fiber
  • Apo-SM complexes utilized by the invention can be used in assays in vitro to measure serum HDL, e.g., for diagnostic purposes. Because ApoA-I, ApoA-II and Apo peptides associate with the HDL component of serum, Apo-SM complexes can be used as "markers" for the HDL population, and the pre-jSl and pre-/32 HDL populations. Moreover, the Apo-SM complexes can be used as markers for the subpopulation of HDL that are effective in RCT.
  • the Apo-SM can be added to or mixed with a patient serum sample; after an appropriate incubation time, the HDL component can be assayed by detecting the incorporated Apo-SM.
  • This can be accomplished using labeled Apo-SM (e.g., radiolabels, fluorescent labels, enzyme labels, dyes, etc.), or by immunoassays using antibodies (or antibody fragments) specific for Apo-SM.
  • labeled Apo-SM can be used in imaging procedures (e.g., CAT scans, MRI scans) to visualize the circulatory system, or to monitor RCT, or to visualize accumulation of HDL at fatty streaks, atherosclerotic lesions, and the like, where the HDL should be active in cholesterol efflux.
  • Phospholipon 90 G silica
  • DPPC dipalmitoyl phosphatidylcholine
  • POPC l-palmitoyl-2-oleyl-phosphatidylcholine
  • a 30mg/ml cholate solution was made by adding 0.9677 g of cholic acid to 32.25 ml of 2mM NaHCO 3 buffer.
  • Phospholipon 90 G (soybean PC) solution
  • Phospholipon 90 G Rh ⁇ ne-Poulenc Nattermann Phospholipid GMBH # 228154
  • a 25 mg/ml Phospholipon 90 G solution was made by adding 0.7815 g of Phospholipon 90 G to 31.26 ml of chloroform.
  • a 25 mg/ml sphingomyelin solution was made by adding 0.0637 g of sphingomyelin to 2.548 ml of chloroform.
  • DPPC l,2-Dipalmitoyl-sn-glycero-3-phosphocholine
  • POPC l-palmitoyl-2-oleyl-phosphatidylcholine
  • cholate solution 160 ml of the 30 mg/ml cholate solution was added to each tube to clarify the sphingomyelin solution.
  • the lipid-cholate solutions were incubated at 37°C (for POPC, SM, and soybean PC) and 50°C (for DPPC). During incubation, solutions were periodically vortexed and sonicated. If solutions would not clear after vortexing and sonicating steps, then additional cholate solution was added to the lipid-cholate solution in a series of 100 ml aliquots. Incubation, vortex, sonication and addition of cholate continued until all solutions became clear. Total cholate solution added was 160, 260, 560 and 560 ml for the SM, DPPC, soybean PC, and POPC, respectively. The lipid-cholate solutions were incubated for a total of 30 min.
  • proApoA-I-lipid-cholate solutions were incubated for 1 h at 37°C (for POPC, SM, and soybean PC) and at 50°C (for DPPC).
  • BIO-BEADS® ion exchange resin
  • BIO-BEADS® were activated by incubation of one volume of dry BIO-BEADS® with two volumes of 2mM NaHCO 3 for 6 hours. Ten ml and 30 ml plastic syringes were loaded with activated BIO-BEADS®. The preparation of proApoA-I-lipid complexes was then loaded onto the BIO-BEADS®. For the sphingomyelin and DPPC solutions, approximately 5-7 ml of BIO-BEADS® were added per 4.8 mg of cholate solution.
  • BIO-BEADS® For soybean PC and POPC, approximately 12 ml of BIO-BEADS® were added per 16.8 mg of cholate solution. The proApoA-I-lipid complex solutions were then loaded on the BIO-BEADS® within the syringes. The syringes were then sealed with barrier film and incubated with rocking at 4°C overnight. At the end of incubation, solutions of the proApo-A-I-lipid complexes were collected and filtered through 0.22 mm PES filters. Solutions were then stored at 4°C prior to the analysis. Complex solutions were analyzed using GPC (gel permeation chromatography) using a 1x30 cm Superdex TM 200 (Pharmacia Biotech) column.
  • GPC gel permeation chromatography
  • aqueous mobile phase containing 20 mM NaHCO 3 (pH 8) was delivered at a 0.5 ml min flow rate.
  • the injection volume was 100 ⁇ l.
  • the run time was 45 min.
  • Complex was detected by abso ⁇ tion at 280 nm.
  • the retention time of the proApoA-I-lipid complex was compared with the retention time of purified rabbit HDL.
  • Chromatograms of proApo-A-I complexes contained two major peaks: the first, appearing at around 22 min, corresponded to a molecular weight of roughly 200-300 kDa. The second, appearing at around 26 min, corresponded to a molecular weight of roughly 100 kDa. In each chromatogram, the peak at 22 min corresponded to lipid-rich proApo-A-I lipid complexes, while the peak at 26 min corresponded to lipid poor proApo-A-I lipid complexes.
  • the chromatogram of purified rabbit HDL standard produced a single peak at around 20 min. Calculated from the retention time of the purified rabbit HDL, the formulation was optimized to yield a monomodal peak at around 22 min of lipid-rich proApo-AI complexes.
  • the ratio between the 22 min and 26 min peaks was differed for different lipids.
  • proApo-A-I-POPC and proApo-A-I-soybean PC complexes at a ratio of 1 : 1.25 protein lipid (wt/wt) the fraction of 26 min peak area, in relation to the total area, was only 10-20%. Therefore, no further optimization was required for these complexes.
  • proApo- A-I-SM and proApo-A-I DPPC complexes at 1:1.25 (wt/wt) protein/lipid ratio the fraction of 26 min peak area in relation to the total area was 30- 50%.
  • Example 1 Based on the results obtained in Section 6.1 (Example 1), the proportion of SM was increased, in order to produce preferentially a single peak of proApoA-I-SM complexes.
  • This example demonstrates that the proApoA-I to sphingomyelin ratio may be varied to produce a single peak of proApoA-I-sphingomyelin complex at a ratio of 1 :2 (wt/wt).
  • ProApoA-I solution in 6M urea (Eurogentec) was concentrated 5 times and dialyzed against 10 volumes of 5 mM NELHCO ⁇ The protein concentration was then measured by performing a Markwell-Lowry protein assay. Protein solution was then lyophilized.
  • a 50 mg/ml stock solution of sphingomyelin was made by dissolving 256.0 mg of sphingomyelin (Avanti) in 5.12 ml of glacial acetic acid.
  • Solutions of pro Apo A-I were combined to weight:weight (wt/wt) ratios of 1:1, 1:1.25, 1:1.5 and 1 :2 by combining 1.0 ml of proApo-A-I stock solution with 0.5, 0.625, 0.75 and 1.0 ml of sphingomyelin stock solution.
  • the combined solutions were filtered using a syringe-driven 0.2 ⁇ m polyethersulfone filter (Whatman) and the volume of filtered solution was recorded.
  • ProApoA-I SM complexes were formed by hydrating the lyophilized powder in bicarbonate saline (140 mM NaCl, 20 mM NaHCO ) to a concentration of 10 mg/ml protein. Solutions were heated to 52°C and cooled to room temperature three times in order to facilitate hydration. Aliquots of 200 ⁇ l of complex solutions were diluted using 200 ⁇ l bicarbonate saline and analyzed on a Superdex 200 HR 10/30 GPC column (Amersham Pharmacia Biotech AB) using the following conditions. Running buffer was 140 mM NaCl and 20 mM NaHCO 3 . The flow rate was 0.5 ml/min. The run time was 50 min. The injection volume was 10 ⁇ l. Detection wavelength was 220 nm. The retention times of complexes was compared to the retention time of a gel filtration standard (Bio-Rad).
  • Chromatograms contained two major peaks at 24 and 29 min.
  • the peak at 24 min corresponded to proApoA-I-SM complexes while the peak at 29 min corresponded to free proApoA-I protein.
  • the ratio between the 24 and 29 min peaks differed depending upon the ratio of pro Apo- A-I-SM with a greater percentage of the peak appearing in the complex portion as the wt/wt ratio increased.
  • wt/wt of proApoA-I :SM a single peak at 24 min was observed, hence, homogeneous distribution of complex size was obtained.
  • EXAMPLE 3 PHARMACOLOGICAL EFFICACY OF r-proApoA-I -SPHINGOMYELIN COMPLEXES COMPARED WITH r-proApoA-I -POPC COMPLEXES
  • ProApoA-I-lipid complexes are drug candidates that potentially mimic the biological activities of HDL.
  • the objective of this study was to compare the pharmacodynamic properties (i.e., mobilization of cholesterol in plasma) of proApoA-I-SM with those of conventional proApoA-I-phosphotidyl choline complexes such as proApoA-I-POPC.
  • Proapohpoprotein A-I comprises six amino acids (Arg-His-Phe-T ⁇ -Gln-Glu) attached at the amino terminal end of Apo A-I.
  • ProApoA-I-SM and proApoA-I-POPC complexes were prepared by the cholate dialysis method as described above.
  • the ratio of apolipoprotein to lipid was 1 :2 (weight of protein/weight of lipid) for proApo A-I-SM and proApo-A-I-POPC.
  • the protein r-proApoA-I (Eurogentec, Belgum) solution in 1 mg/ml in 6M urea was dialyzed with 20 volumes of 5 mM NH_ 4 HCO 3 solution (pH 8). Protein concentration after dialysis was determined by a Modified Lowry Assay.
  • Sodium cholate (Sigma) was added to the protein solution at a 1 :2 ratio (weight of r-proApoA-I/weight of sodium cholate). Then phosphohpids were added to the protein-cholate solutions at a 1 :2 weight ratio of apolipoprotein to phospholipid.
  • Protein-cholate-phospholipid solutions were incubated at 37°C for solutions containing POPC and 50°C for solutions containing SM. During incubation solutions were periodically mixed by vortexing.
  • apohpoprotein-phosphohpid complexes were analyzed to determine their size, protein concentration, solution pH and osmolality. Complex sizes were analyzed using GPC (gel permeation chromatography) equipped with a 1x30 cm SuperdexTM 200 (Pharmacia Biotech) column. An aqueous mobile phase containing 20 mM NaHCO (pH 8) was delivered at a 0.5 ml/min flow rate. The injection volume was 100 ⁇ l. Complexes were detected by UV abso ⁇ tion at 280 nm. Protein concentration was determined by routine methods (i.e., a modified Markwell Lowry assay). Animal studies design Random-bred, NZW female rabbits weighing approximately 3 - 3.6 kg were used in this study.
  • the apohpoprotein-phosphohpid complexes were injected intravenously by slow bolus infusion into the marginal ear vein.
  • approximately 1-2 ml of blood was collected from the lateral ear vein in the non-injection ear (or in some cases, from the medial artery) using a 3 ml syringe without anticoagulant. All tubes collected without anticoagulant were kept at room temperature for 30-60 min for clotting. Blood samples were centrifuged within 1 hour after collection and the serum from each sample was separated into aliquots and stored a -80°C until time of analysis.
  • Serum phospholipid Purpholipid B, Kit # 990-54009, Wako Chemicals GmbH, Neuss, Germany
  • triglycerides Teriglycerides, Kit # 1488872, Boehringer Mannheim Co ⁇ oration, Indianapolis, IN
  • total cholesterol and unesterified cholesterol were determined with commercially available kits for a Hitachi 912 Automatic Analyzer (Roche Diagnostics Co ⁇ oration, Indianapolis, IN).
  • Lipoprotein profiles were analyzed using gel filtration chromatography on a Superose 6HR lx 30 cm column equipped with on-line detection for total or free cholesterol as described by Kieft et al. (J Lipid Res 1991; 32:859-866, 1991). Esterified cholesterol in serum and in the lipoprotein fractions VLDL, LDL and HDL was calculated by subtracting free cholesterol from total cholesterol values.
  • ProApoA-I-SM and proApoA-I-POPC complexes (1 :2 ratio of protein weight phospholipid weight) were administered at 15 mg/kg dose (based on protein content) to NZW female rabbits.
  • a significantly higher mobilization of free cholesterol was observed with administration of proApo-I-SM complexes compared to proApo-I-POPC complexes.
  • the HDL free cholesterol increased by 31 mg/dl after 30 min following administration of proApo A-I-SM versus by 7 mg/dl 30 min following administration of proApoA-I-POPC complexes (FIG. 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03734054A 2002-05-17 2003-05-16 Verfahren zur behandlung dyslipidämischer störungen Withdrawn EP1511508A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38151202P 2002-05-17 2002-05-17
US381512P 2002-05-17
PCT/US2003/015467 WO2003096983A2 (en) 2002-05-17 2003-05-16 Method of treating dyslipidemic disorders

Publications (2)

Publication Number Publication Date
EP1511508A2 EP1511508A2 (de) 2005-03-09
EP1511508A4 true EP1511508A4 (de) 2009-07-08

Family

ID=29550136

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03734054A Withdrawn EP1511508A4 (de) 2002-05-17 2003-05-16 Verfahren zur behandlung dyslipidämischer störungen

Country Status (8)

Country Link
US (2) US20040067873A1 (de)
EP (1) EP1511508A4 (de)
JP (1) JP2006507223A (de)
AU (1) AU2003239489A1 (de)
BR (1) BR0310099A (de)
CA (1) CA2486127C (de)
MX (1) MXPA04011312A (de)
WO (1) WO2003096983A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968529B2 (en) 2003-01-20 2011-06-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
EP1576894A1 (de) * 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS
AU2005220692A1 (en) * 2004-03-16 2005-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
AU2005310341A1 (en) 2004-11-30 2006-06-08 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
CA2619943A1 (en) * 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
WO2007137400A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
ES2376396T3 (es) * 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2939683B1 (de) * 2009-02-16 2017-01-04 Cerenis Therapeutics Holding SA Apolipoprotein A-I-Mimetika
WO2010131718A1 (ja) * 2009-05-13 2010-11-18 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
AU2011274238B2 (en) * 2010-06-30 2013-09-26 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
AR082644A1 (es) 2010-08-30 2012-12-19 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares
ES2716349T3 (es) 2011-02-07 2019-06-12 Cerenis Therapeutics Holding Sa Complejos de lipoproteínas y fabricación y usos de los mismos
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用
SG11201402556RA (en) * 2011-12-21 2014-10-30 Csl Ltd Dosage regime for apolipoprotein formulations
WO2014011908A1 (en) * 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
BR112016025470A2 (pt) 2014-05-02 2017-08-15 Cerenis Therapeutics Holding S A ?hdl terapêutico?
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR20180027532A (ko) 2015-07-10 2018-03-14 펩티노보 바이오파마, 엘엘씨 소수성 약물의 효능 개선용 제형
BR112019007709A2 (pt) 2016-11-10 2019-07-09 Csl Ltd lipoproteína de alta densidade reconstituída para o tratamento de infarto do miocárdio
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
US20190048049A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Cargomers
EP4135747A1 (de) 2020-04-16 2023-02-22 Abionyx Pharma SA Verfahren zur behandlung von akuten erkrankungen mit lipidbindenden komplexen auf proteinbasis
AU2021354095A1 (en) 2020-10-01 2023-06-08 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
EP4322746A1 (de) 2021-04-15 2024-02-21 Abionyx Pharma SA Verwendung von lipidbindenden proteinbasierten komplexen in lösungen zur organkonservierung
WO2023196804A1 (en) * 2022-04-04 2023-10-12 Phyto Tech Corp. Use of apolipoprotein a-v as an oral ingestible protein for nutraceutical or pharmaceutical applications
JP2025512987A (ja) 2022-04-06 2025-04-22 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法
JP2025511845A (ja) 2022-04-06 2025-04-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
WO1999016459A1 (en) * 1997-09-29 1999-04-08 Dasseux Jean Louis Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
WO2001058492A2 (en) * 2000-02-14 2001-08-16 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
CA2137814A1 (en) 1992-06-12 1993-12-23 Maryvonne Rosseneu New peptides and proteins, process for their preparation and their use as cholesterol acceptors
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
US6258596B1 (en) * 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
JP2000509020A (ja) 1996-03-29 2000-07-18 ダリオ・ボッフェリ コレステロールおよび他の脂質の取り込みを阻害する両親媒性分子
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6267377B1 (en) * 1999-11-12 2001-07-31 Herman W. Griggs Astronomy-based card game
WO2002030359A2 (en) 2000-10-13 2002-04-18 University Of Cincinnati Methods for enhancing lysing of coagulated blood with apolipoprotein e2 phenotype
IL165253A0 (en) 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152632A (ja) * 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
WO1999016459A1 (en) * 1997-09-29 1999-04-08 Dasseux Jean Louis Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
WO2001058492A2 (en) * 2000-02-14 2001-08-16 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARMENA R: "STATINS: MONOTHERAPY OR COMBINATION STRATEGY FOR THE TREATMENT OF DYSLIPIDEMIA", HEART DRUG, KARGER, BASEL, CH, vol. 2, no. 4, 1 January 2002 (2002-01-01), pages 175 - 183, XP009019893, ISSN: 1422-9528 *
ERIKSSON MATS ET AL: "Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 100, no. 6, 10 August 1999 (1999-08-10), pages 594 - 598, XP009117409, ISSN: 0009-7322 *
MODRAK DAVID E ET AL: "Sphingomyelin potentiates chemotherapy of human cancer xenografts", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 268, no. 2, 16 February 2000 (2000-02-16), pages 603 - 606, XP009117442, ISSN: 0006-291X *
SCHMELZ E M ET AL: "SPHINGOMYELIN CONSUMPTION SUPPRESSES ABERRANT COLONIC CRYPT FOCI AND INCREASES THE PROPORTION OF ADENOMAS VERSUS ADENOCARCINOMAS IN CF1 MICE TREATED WITH 1,2-DIMETHYLHYDRAZINE: IMPLICATIONS FOR DIETARY SPHINGOLIPIDS AND COLON CARCINOGENESIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 56, no. 21, 1 November 1996 (1996-11-01), pages 4936 - 4941, XP008021439, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CA2486127A1 (en) 2003-11-27
WO2003096983A2 (en) 2003-11-27
AU2003239489A8 (en) 2003-12-02
EP1511508A2 (de) 2005-03-09
US20040067873A1 (en) 2004-04-08
CA2486127C (en) 2014-03-11
US20080269111A1 (en) 2008-10-30
JP2006507223A (ja) 2006-03-02
WO2003096983A3 (en) 2005-01-13
MXPA04011312A (es) 2005-02-14
AU2003239489A1 (en) 2003-12-02
US7994120B2 (en) 2011-08-09
BR0310099A (pt) 2007-03-20

Similar Documents

Publication Publication Date Title
US7994120B2 (en) Method of treating dyslipidemic disorder
US11801282B2 (en) Charged lipoprotein complexes and their uses
JP2008534487A5 (de)
AU2012202223B2 (en) Charged lipoprotein complexes and their uses
HK1155389A (en) Charged lipoprotein complexes and their uses
HK1156840B (en) Charged lipoprotein complexes and their uses
HK1115823B (en) Charged lipoprotein complexes and their uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: REA, THOMAS, J.

Inventor name: SCHWENDEMAN, ANNA, A.

Inventor name: DASSEUX, JEAN-LOUIS, H.

A4 Supplementary search report drawn up and despatched

Effective date: 20090609

17Q First examination report despatched

Effective date: 20090929

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111220